ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hetland, G.
Right arrow Articles by Fosse, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hetland, G.
Right arrow Articles by Fosse, E.

Ann Thorac Surg 1997;63:1076-1080
© 1997 The Society of Thoracic Surgeons

Original Article: Cardiovascular

Both Plasma- and Leukocyte-Associated C5a Are Essential for Assessment of C5a Generation In Vivo

Geir Hetland, MD, PhD, Oddvar Moen, MD, Kåre Bergh, MD, PhD, Kolbjørn Högåsen, MD, PhD, C. Erik Hack, MD, PhD, Tom Eirik Mollnes, MD, PhD, Erik Fosse, MD, PhD

Institute for Immunology and Rheumatology, The National Hospital, Oslo, Norway

Accepted for publication November 1, 1996.

Background. Measurement of C5a in plasma is hampered by the rapid clearance of C5a as a result of cell binding. Therefore, an assessment of whether cell-bound C5a might better reflect C5a generation in vivo is essential.

Methods. We quantified plasma and leukocyte-bound C5a in samples from patients undergoing cardiopulmonary bypass, which is known to be associated with complement activation. C3 activation products and the terminal complement complex were measured as well.

Results. Plasma levels of C3 activation products and the terminal complement complex increased rapidly and significantly after the onset of cardiopulmonary bypass until they reached a plateau after 30 minutes. The concentration of plasma C5a increased steadily to twice baseline at the end of bypass. The concentration of leukocyte-associated C5a increased threefold after 10 minutes of cardiopulmonary bypass, when a plateau was reached. A positive correlation was found between levels of plasma C3 activation products or terminal complement complex and plasma C5a plus cell-associated C5a but not between C3 activation products or terminal complement complex and either one of the C5a variables.

Conclusions. We conclude that both plasma C5a and leukocyte-associated C5a are needed for monitoring in vivo C5a generation.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
V. Videm, T. E. Mollnes, K. Bergh, E. Fosse, B. Mohr, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig
HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. II. MECHANISMS FOR REDUCED COMPLEMENT ACTIVATION IN VIVO
J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 803 - 809.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.